Bussiness6 months ago
Summit Therapeutics’ Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck’s Multi-Billion Keytruda In China Study
Summit Therapeutics’ Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck’s Multi-Billion Keytruda In China Study On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading...
